Myriad Genetics (MYGN) Projected to Post Earnings on Tuesday

Myriad Genetics (NASDAQ:MYGN) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $200.37 million for the quarter.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. The business had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Stock Performance

Shares of MYGN opened at $7.36 on Tuesday. The firm’s 50 day moving average price is $9.40 and its two-hundred day moving average price is $13.50. Myriad Genetics has a twelve month low of $7.16 and a twelve month high of $29.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The firm has a market cap of $678.47 million, a P/E ratio of -5.66 and a beta of 1.87.

Analysts Set New Price Targets

A number of brokerages have weighed in on MYGN. Bank of America decreased their price target on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a report on Monday, March 3rd. Raymond James reissued an “outperform” rating and issued a $19.00 price target (down from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. Stephens restated an “equal weight” rating and issued a $20.00 price target on shares of Myriad Genetics in a research report on Thursday, January 16th. Guggenheim downgraded shares of Myriad Genetics from a “buy” rating to a “neutral” rating in a report on Wednesday, April 9th. Finally, Piper Sandler raised Myriad Genetics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $11.50 to $12.50 in a research report on Wednesday, March 12th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $20.61.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.